NEW YORK (GenomeWeb) – A team led by researchers at the Broad Institute and the University of California, Berkeley has engineered new CRISPR-Cas9 variants that widen the targeting scope of base editors, thus broadening the number of human pathogenic variants that could potentially targeted.